Xponance’s Soleno Therapeutics SLNO Stock Holding History

Xponance’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,259	Closed	-$220K	–	1603
2025 Q3	$220K	Buy	3,259 +153	+5%	+$11.3K	﹤0.01%	1320
2025 Q2	$260K	Buy	+3,106	New	+$232K	﹤0.01%	1199

Other funds holding SLNO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Xponance's SLNO Position: Q4 2025 in Review

Xponance sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 3,259 shares — an estimated $220K sold.

Xponance first reported a position in SLNO in Q2 2025 and held it in 2 quarters. The position peaked at $260K in Q2 2025. 248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

Xponance reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
Xponance sold 3,259 Soleno Therapeutics shares in Q4 2025, an estimated $220K.
Xponance first reported a position in Soleno Therapeutics in Q2 2025 and held it in 2 quarters.
Xponance's Soleno Therapeutics position peaked at $260K in Q2 2025.
248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on Xponance's 13F filing for Q4 2025, filed 12 Feb 2026.